The company's bottom line came in at -$215.33 million, or -$3.35 per share. This compares with -$154.94 million, or -$3.00 per share, last year. The company's revenue for the period fell 17.8% to ...
This page features the latest Merus share stories and breaking news. Assess the latest information about the Merus stock. Our team of expert financial journalists are ready to bring you today's top ...
Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA... Merus (NASDAQ:MRUS) N.V. (Nasdaq: MRUS) (Merus, the Company, we, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results